Who is the CEO of Kymera?
We continue to stay focused on our mission of building a fully integrated biopharmaceutical company focused on discovering and developing oral drugs with biologics-like activity,” said Nello Mainolfi, Ph. D. Founder, President and CEO, Kymera Therapeutics. Kymera Therapeutics’s competitors and similar companies include Foghorn Therapeutics, XBiotech, Adicet Bio and Jnana.
Who owns Kymera?
Palladium Equity Partners Acquires Kymera International from Platinum Equity. Kymera International is a world-renowned leader in manufacturing specialty metals and coatings. Our innovative solutions consistently redefine possibilities across a variety of industries, including aerospace, automotive, healthcare, and beyond.
What is the net worth of Kymera Therapeutics?
kymera therapeutics market cap kymera therapeutics has a market cap or net worth of $1. B as of apr 05, 2025. Based on analyst ratings, kymera therapeutics’s 12-month average price target is $55. What is kymr’s upside potential, based on the analysts’ average price target? Kymera therapeutics has 149.The average price target for Kymera Therapeutics is $55. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $72. The average price target represents 149. Increase from the current price of $22.
What rarity is Kymera?
Kymera is a Legendary Outfit in Fortnite, that could have been obtained immediately after purchasing the Chapter 2: Season 7 Battle Pass. Purchasing the battle pass immediately unlocks the base Kymera outfit. Using the new Fortnite alien artifacts, you can purchase new styles to create your own Kymera that looks unlike anyone else’s alien.
How many employees does Kymera have?
Kymera Therapeutics had 188 employees as of December 31, 2024. The number of employees increased by 1 or 0. When did Kymera Therapeutics go public? Kymera Therapeutics completed its IPO on August 20, 2020.
What does Kymera Therapeutics do?
Kymera is a clinical-stage biotechnology company working to reinvent the treatment of human disease through the development of innovative, highly differentiated medicines that address critical health problems and dramatically improve patients’ lives. Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives.